Fibrolamellar hepatocellular carcinoma - wikidoc
Fibrolamellar hepatocellular carcinoma (FLC) is a rare subtype of primary liver cancer. Fibrolamellar hepatocellular carcinoma was first described Edmondson in 1956. Fibrolamellar hepatocellular carcinoma is most commonly seen in children and young adults. The pathogenesis of fibrolamellar hepatocellular carcinoma is characterized by the lack of cirrhosis. Common causes of fibrolamellar hepatocellular carcinoma, include: active hepatic inflammation, hepatitis B or C viral infection, alcohol-related liver disease, nonalcoholic fatty liver disease, and dietary aflatoxin B1. The majority of patients with fibrolamellar hepatocellular carcinoma remain asymptomatic for years. Early clinical features include abdominal pain, weight loss, and malaise. If left untreated, the majority of patients with ...http://es.wikidoc.org/index.php/Fibrolamellar_hepatocellular_carcinoma
Gefitinib in Treating Patients With Advanced Unresectable Hepatocellular Carcinoma (Liver Cancer) - Full Text View -...
PRIMARY OBJECTIVES:. I. Evaluate the ability of ZD1839 to improve progression free survival in patients with advanced unresectable hepatocellular carcinoma.. II. Evaluate response rate of ZD1839 in advanced unresectable hepatocellular carcinoma.. III. Evaluate the effect of ZD1839 on measurable disease in patients with unresectable hepatocellular carcinoma.. IV. Evaluate the effect of ZD1839 on serum alpha-fetoprotein levels in patients with abnormal pretreatment serum levels.. V. Evaluate toxicity of ZD1839 in advanced unresectable hepatocellular carcinoma.. VI. Investigate biologic markers for outcome in patients with unresectable hepatocellular carcinoma treated with ZD1839.. OUTLINE: This is a multicenter study.. Patients receive oral gefitinib daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or ...https://clinicaltrials.gov/ct2/show/NCT00071994?cond=%22Liver+Neoplasms%22&rank=16
Profile of Tumor Antigen-Specific CD8 T Cells in Patients With Hepatitis B Virus-Related Hepatocellular Carcinoma | ScholarBank...
Gehring, A.J., Ho, Z.Z., Tan, A.T., Bertoletti, A., Aung, M.O., Lim, S.G., Lee, K.H., Tan, K.C., Lim, S.G. (2009). Profile of Tumor Antigen-Specific CD8 T Cells in Patients With Hepatitis B Virus-Related Hepatocellular Carcinoma. Gastroenterology 137 (2) : 682-690. ScholarBank@NUS Repository. https://doi.org/10.1053/j.gastro.2009.04. ...http://scholarbank.nus.edu.sg/handle/10635/26739
Fibrolamellar hepatocellular carcinoma - Wikipedia
Fibrolamellar hepatocellular carcinoma (FHCC) is a rare form of hepatocellular carcinoma (HCC) that typically affects young adults and is characterized, under the microscope, by laminated fibrous layers interspersed between the tumour cells. Approximately 200 new cases are diagnosed worldwide each year. A recent study showed the presence of the DNAJB1-PRKACA chimeric transcript (resulting from a 400kb somatic deletion on chromosome 19) in 100% of the FHCCs examined (15/15) This gene fusion has been confirmed in a second study. The histopathology of FHCC is characterized by laminated fibrous layers, interspersed between the tumor cells. Cytologically, the tumor cells have a low nuclear to cytoplasmic ratio with abundant eosinophilic cytoplasm. Tumors are non-encapsulated, but well circumscribed, when compared to conventional HCC (which typically has an invasive border). Due to lack of symptoms, until the tumor is sizable, this form of cancer ...https://en.wikipedia.org/wiki/Fibrolamellar_hepatocellular_carcinoma
Mutation pattern of the p53 gene as a diagnostic marker for multiple hepatocellular carcinoma | IRIS Verona
Hepatocellular carcinoma, sometimes shows multiple tumor nodules, therefore poses a problem of differential diagnosis between cancers of multifocal and those of metastatic origin. Conventionally, pathological criteria have been used for this purpose, but these are largely subjective. In order to facilitate more objective differential diagnosis of multiple hepatocellular carcinoma, we used the pattern of mutation of the p53 gene as a marker for each tumor nodule. We studied 58 nodules from 26 cases of multiple hepatocellular carcinoma using polymerase chain reaction-single strand conformation polymorphism analysis, a simple method for detecting mutations. p53 gene mutations were detected in 65% (17 of 26) of cases. The internodule mutation patterns were heterogeneous in 11 cases and homogeneous in 6, enabling a multifocal origin to be diagnosed in the former and a metastatic origin in the latter at the ...https://iris.univr.it/handle/11562/4248
Diagnostic value of PIVKA-II and alpha-fetoprotein in hepatitis B virus-associated hepatocellular carcinoma. | Sigma-Aldrich
Sigma-Aldrich offers abstracts and full-text articles by [Seung In Seo, Hyoung Su Kim, Won Jin Kim, Woon Geon Shin, Doo Jin Kim, Kyung Ho Kim, Myoung Kuk Jang, Jin Heon Lee, Joo Seop Kim, Hak Yang Kim, Dong Joon Kim, Myung Seok Lee, Choong Kee Park].https://www.sigmaaldrich.com/catalog/papers/25852278
European Cases of Fibrolamellar Hepatocellular Carcinoma | Annals of Internal Medicine | American College of Physicians
To the editor: We are writing in response to the letter (1) on fibrolamellar hepatocellular carcinoma, in which Ruffin points out that the cases of this tumor reported since 1941 have all originated in the United States. We report two cases of this tumor diagnosed in patients treated at our hospital.. A 25-year-old man was hospitalized for epigastric discomfort; anorexia was present for 5 months. Physical examination showed a liver edge 12 cm below the right costal margin. The erythrocyte sedimentation rate was 135 mm/h; alkaline phosphatase, 100 U/L (normal, ≤ 40 U/L); and gamma-glutamyltransferase, 89 IU/L (normal, ≤ 30 ...http://annals.org/aim/article-abstract/702929/european-cases-fibrolamellar-hepatocellular-carcinoma
Dynamic monitoring of serum alpha-fetoprotein and its correlation with early hepatocellular carcinoma in patients with chronic...
Dynamic monitoring of serum alpha-fetoprotein and its correlation with early hepatocellular carcinoma in patients with chronic hepatitis B, Qing-Feng Chen, Xiao-Min Luo, Mei-Ping Zhttp://www.alliedacademies.org/articles/dynamic-monitoring-of-serum-alphafetoprotein-and-its-correlation-with-early-hepatocellular-carcinoma-in-patients-with-chronic-hepa-8517.html
Sorafenib With Capecitabine and Oxaliplatin for Advanced or Metastatic Hepatocellular Carcinoma - Full Text View -...
Hepatocellular carcinoma (HCC) is the most common primary liver malignancy, with an annual incidence of over 500,000 new patients and more than half of the new cases occur in China. The most common etiological causes of HCC are hepatitis B and hepatitis C viral infections.. HCC is a cancer of high particular relevance in Hong Kong because of the high prevalence (10%) of hepatitis B virus infection in the population. It is the second most common cancer causing death in Hong Kong. Surgical resection and liver transplantation are regarded as the main curative treatments for HCC. Nevertheless, the majority of patients have unresectable HCCs because of advanced tumor stage and poor liver function. Besides, transplantation is indicated only for early small HCCs, and its application is limited by the shortage of liver graft, which is a particularly severe problem in Hong Kong.. HCC is an aggressive, largely chemo-resistant cancer with a poor prognosis, currently there is no ...https://clinicaltrials.gov/ct2/show/NCT00752063?recr=Open&cond=%22Carcinoma%2C+Hepatocellular%22&rank=6
Shoulder Mass as the Initial Presentation of Metastatic Hepatocellular Carcinoma | ACG Case Reports Journal - An online journal...
HCC is the third most common cancer worldwide, causing about 700,000 deaths annually.2 It is associated with cirrhosis, hepatitis B and C virus, primary biliary and sclerosing cholangitis, aflatoxins, and autoimmune hepatitis.2,3 Extrahepatic metastatic HCC, as observed in this case, occur in 30-50% of HCC patients; the most common sites are lungs, bones, adrenal glands, and lymph nodes.4 Rare and unusual metastatic sites have been described in the literature, including the chest wall presenting as a breast mass and metastasis to the nasal septum.5,6 Indeed, extrahepatic metastases to the humeral shoulder, chest wall, and bony lesions are exceedingly rare, as only a handful of cases have been reported.3,7 Traditionally, a few systems have been widely employed for HCC staging (e.g. Okuda, tumor/node/metastasis), however, newer classification systems that take into account prognostication and treatment regimens are increasingly being utilized.8 The Cancer of the Liver Italian Program (CLIP) and ...http://acgcasereports.gi.org/shoulder-mass-as-the-initial-presentation-of-metastatic-hepatocellular-carcinoma/
Gentaur Molecular :US Biomax \ Hepatocellular carcinoma tissue array, 63 cases 63 cores, replaced by LV809 \ BS03014
Gentaur molecular products has all kinds of products like :search , US Biomax \ Hepatocellular carcinoma tissue array, 63 cases_63 cores, replaced by LV809 \ BS03014 for more molecular products just contact ushttp://www.antibody-antibodies.com/product_det.php?id=1004951&supplier=search&name=Hepatocellular%20carcinoma%20tissue%20array,%2063%20cases_63%20cores,%20replaced%20by%20LV809
Diagnostics | Free Full-Text | Hepatocellular Carcinoma, Fibrolamellar Variant: Diagnostic Pathologic Criteria and Molecular...
Fibrolamellar hepatocellular carcinoma (FL-HCC) is generally a fairly rare event in routine pathology practice. This variant of hepatocellular carcinoma (HCC) is peculiarly intriguing and,in addition, poorly understood. Young people or children are often the target individuals with this type of cancer. Previously, I highlighted some pathology aspects of FL-HCC, but in this review, the distinctive clinico-pathologic features of FL-HCC and the diagnostic pathologic criteria of FL-HCC are fractionally reviewed and expanded upon. Further, molecular genetics update data with reference to this specific tumor are particularly highlighted as a primer for general pathologists and pediatric histopathologists. FL-HCC may present with metastases, and regional lymph nodes may be sites of metastatic spread. However, peritoneal and pulmonary metastatic foci have also been reported. To the best of our knowledge, FL-HCC was initially considered having an ...http://www.mdpi.com/2075-4418/6/1/3/htm
CD80 transfected human hepatocellular carcinoma cells activate cytotoxic T lymphocytes to target HCC cells with shared tumor...
CD80 transfected human hepatocellular carcinoma cells activate cytotoxic T lymphocytes to target HCC cells with shared tumor antigenshttp://cell-lines.toku-e.com/Reference_194.html
Safety and efficacy of TACE and gamma knife on hepatocellular carcinoma with portal vein invasion | Gut
We read with interest the article by Bruix et al1 in which Sorafenib was regarded as the standard treatment for hepatocellular carcinoma (HCC) patients with portal vein tumour thrombosis (PVTT). However, Sorafenib can only confer 2-3 months of overall survival (OS) benefit2 ,3 and is inapplicable to many patients due to extensive side effects and high price. Zhong et al4 proposed that liver resection might provide survival benefit to patients with HCC-PVTT with adequate liver function. However, this proposal was based on literature survey, lacked definite patient inclusion criteria and failed to provide information on patients' baseline characteristics. Therefore, explorations of alternative therapeutics for patients with HCC-PVTT are still needed.. Although not recommended by mainstream guidelines5 ,6 for patients with HCC-PVTT, transarterial chemoembolisation (TACE) has long been practiced in the clinic in selected patients with HCC-PVTT.7 ,8 Gamma knife surgery (GKS) has ...http://gut.bmj.com/content/65/4/715
Most recent papers with the keyword Vascular Surgery Clinical Trials | Read by QxMD
BACKGROUND: Sorafenib is the recommended treatment for patients with advanced hepatocellular carcinoma. We aimed to compare the efficacy and safety of sorafenib to that of selective internal radiotherapy (SIRT) with yttrium-90 ((90)Y) resin microspheres in patients with hepatocellular carcinoma. METHODS: SARAH was a multicentre, open-label, randomised, controlled, investigator-initiated, phase 3 trial done at 25 centres specialising in liver diseases in France. Patients were eligible if they were aged at least 18 years with a life expectancy greater than 3 months, had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, Child-Pugh liver function class A or B score of 7 or lower, and locally advanced hepatocellular carcinoma (Barcelona Clinic Liver Cancer [BCLC] stage C), or new hepatocellular carcinoma not eligible for surgical resection, liver ...https://www.readbyqxmd.com/keyword/107595
Cetuximab in Patients With Unresectable or Metastatic Hepatocellular Carcinoma - Full Text View - ClinicalTrials.gov
The first step in this study is to examine the tumor biopsy (previously collected) and determine whether or not it is epidermal growth factor receptor (EGFR) positive or EGFR negative. Both EGFR positive and EGFR negative patients can participate in this study because at this time it is not known whether having a negative or positive receptor makes a difference in how the study drug works on the tumor. By knowing if the tumor is EGFR positive or negative, we will be able to see if there is a difference in the way the tumor responds to cetuximab.. Patients will receive cetuximab intravenously once weekly for 6 weeks. Each 6-week period is one cycle of treatment. The first dose of cetuximab is larger than the following doses.. For the first clinic visit the patient's blood pressure, temperature, breathing and heart rate will be taken before, during, at the end, and one-hour after the cetuximab has been administered. For each visit after that, blood pressure, temperature, breathing and heart rate ...https://clinicaltrials.gov/ct2/show/NCT00142428
Phase IIA Exploratory Study of Oral Milciclib Maleate in Patients With Unresectable or Metastatic Hepatocellular Carcinoma -...
The primary aim of this exploratory dose-ranging study is to test the safety and tolerability of milciclib when administered orally at 100 mg in patients withhttp://adisinsight.springer.com/trials/700261042
Novel proteomic biomarker panel for prediction of aggressive metastatic hepatocellular carcinoma relapse in surgically...
Sigma-Aldrich offers abstracts and full-text articles by [Gek San Tan, Kiat Hon Lim, Hwee Tong Tan, May Lee Khoo, Sze Huey Tan, Han Chong Toh, Maxey Ching Ming Chung].https://www.sigmaaldrich.com/catalog/papers/24946162
Cell culture. Human hepatocellular carcinoma cell line (Hep3B), human colorectal carcinoma cell line (SW620), and human normal lung fibroblast cell lines (NHLF and MRC5) were obtained from the American Type Culture Collection. Human hepatocellular carcinoma cell lines (BEL7404 and SMMC7721) and human normal liver cell lines (QSG7701 and L-02) were purchased from the Shanghai Cell Collection. HEK293 was obtained from Microbix Biosystems, Inc. Cells were maintained in humidified 37°C atmosphere containing 5% CO2 and cultured in DMEM (Life Technologies) supplemented with 10% heat-inactivated fetal bovine serum (Life Technologies), 4 mmol/L glutamine, 50 units/mL penicillin, and 50 μg/mL streptomycin.. Virus construction and production. The constructs including pCN205-EGFP and pCN205-IL-24 were generated according to the standard molecular cloning protocol. The homologous recombination between pCN205-EGFP and pCN205-IL-24 ...http://clincancerres.aacrjournals.org/content/14/8/2450
Racial differences among hepatocellular carcinoma survival have already been reported, but - biobender.com
Racial differences among hepatocellular carcinoma survival have already been reported, but the etiology behind these disparities remains unclear. in screening and early detection, hepatocellular carcinoma retains a poor prognosis, with overall 1- and 5-year survival rates of 23 and 5%, respectively [8, 9]. However, small, localized tumors may be more amenable to curative therapy and substantially improved survival [8C13]. The emergence of more effective screening and surveillance protocols, combined with improvements in curative therapy for early stage cancers, provides the opportunity to determine populations that may advantage most from intrusive therapies and check out modifiable disparities in the use of these treatments. Latest studies possess reported racial/cultural variants in the increasing occurrence of hepatocellular carcinoma [14C18]. Some also have recommended that racial/cultural variations can ...http://biobender.com/2017/09/racial-differences-among-hepatocellular-carcinoma-survival-have-already-been-reported-but/
Hepatocellular Carcinoma. Read about Hepatocellular Carcinoma | Patient
In most cases, hepatocellular carcinoma develops in patients with chronic liver disease (70-90% of all patients). More about Hepatocellular Carcinomahttps://patient.info/doctor/primary-liver-cancer-pro
Transarterial embolization and percutaneous ethanol injection as an effective bridge therapy before liver transplantation for...
Background. Transarterial chemoembolization alone or in association with radiofrequency ablation is an effective bridging strategy for patients with hepatocellular carcinoma awaiting for a liver transplant.However, cost of this therapymay limit its utilization. This study was designed to evaluate the outcomes of a protocol involving transarterial embolization, percutaneous ethanol injection, or both methods for bridging hepatocellular carcinomas prior to liver transplantation. Methods. Retrospective review of all consecutive adult patients who underwent a first liver transplant as a treatment to hepatitis C-related hepatocellular carcinoma at our institution between 2002 and 2012. Primary endpoint was patient survival. Secondary endpoint was complete tumor necrosis. Results. Forty patients were analyzed, age 58 ± 7 years.There were 23 males (57.5%). Thirty-six (90%) out of the total 40 patients were within ...http://www.lume.ufrgs.br/handle/10183/159330
Specific targeting of human hepatocellular carcinoma cells by immunoliposomes in vitro. - Semantic Scholar
The monoclonal antibody AF-20 was raised against the human hepatocellular carcinoma (HCC) cell line FOCUS and binds with high affinity to a rapidly internalized 180-kd homodimeric glycoprotein that is abundantly expressed on the surface of human HCC and other human cancer cell lines. Immunoliposomes were produced by covalently coupling AF-20 to liposomes containing carboxyfluorescein. Interaction of immunoliposomes with various HCC cell lines in vitro was quantitatively assessed by flow cytometry and qualitatively analyzed by fluorescence microscopy. Liposomes bearing an isotype-matched nonrelevant monoclonal antibody (MAb) and cell lines not expressing AF-20 antigen served as controls. AF-20-immunoliposomes specifically bound to HCC and other human cancer cell lines expressing the AF-20 antigen and were rapidly internalized at 37 degrees C. Interaction of AF-20-conjugated liposomes with these cell lines was between 5 and 200 times greater than that of unconjugated ...https://www.semanticscholar.org/paper/Specific-targeting-of-human-hepatocellular-carcino-Moradpour-Compagnon/d356d01e0eecd5b6170f407d701a03c7c14455af
Expression of CD105 (Endoglin) in Hepatocellular Carcinoma and Correlation with Intrahepatic Metastasis: Analysis Using Tissue...
Neovascularization provides the route for nutrient supply to the tumor and the conduit for tumor cells to be shed into the circulation. CD31 is a pan-endothelial cell marker and CD105 is an active endothelial cell marker, but whether there is a link between CD105 expression and metastasis in Hepatocellular carcinoma (HCC) still remains unclear. A tissue microarray containing 38 HCCs and adjacent non-tumorous liver tissue samples was constructed. The microvessel density (MVD) of CD31, CD105, vWF and the expression of PCNA, VEGF were investigated in a HCC tissue microarray by immunohistochemistry. There was a significant difference between the score of MVD-CD31 in HCC (48.5 ± 29.7) and non-tumorous liver tissue (24.2 ± 22.3, P|0.01). The mean score of MVD-CD31 was higher in HCCs with high PCNA expression (68.4 ± 37.0) than in HCCs with low PCNA expression (37.9 ± 30.9, P = 0.012). MVD-CD105 and VEGF expression were significantly higher in HCC with intrahepatic metastasis (P | ...https://www.semanticscholar.org/paper/Expression-of-CD105-Endoglin-in-Hepatocellular-Car-Hou-Mori/48c16c6d1e0575f72c27a76179774393efec23e9
Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR....
Advanced hepatocellular carcinoma (HCC) not eligible for local therapies has limited chances of cure. Sorafenib is a multikinase inhibitor with proven activity in advanced HCC. Octreotide is used in thttps://link.springer.com/article/10.1007%2Fs00280-009-1226-z